Eli Lilly Acquires Kelonia Therapeutics, Securing In Vivo CAR-T Therapy 'KLN-1010' Targeting BCMA
Innovative Deal Structure and Acquisition Rationale
Eli Lilly and Company has entered into a definitive agreement to acquire Kelonia Therapeutics, a privately held biotechnology company, for a total of $7 billion (approximately $9.5 billion). The deal includes an upfront payment of $3.25 billion and milestone payments of $3.75 billion. Lilly's significant investment aims to secure a key platform that can overcome the limitations of existing cell therapies. This reflects the recognition of the unique technological value of the therapy, despite being in the early stages of clinical development.
Value of In Vivo Gene Delivery Technology
The core assets acquired in the acquisition are Kelonia's proprietary 'In Vivo Gene Positioning System (iGPS®)' technology and the multiple myeloma therapy candidate 'KLN-1010' based on this platform. Unlike the conventional ex vivo approach, which involves extracting immune cells and editing their genes outside the patient's body, this technology directly delivers lentiviral particles to T cells in vivo, generating CAR-T cells that target the B-cell maturation antigen (BCMA). This significantly reduces the time and cost associated with the manufacturing process and greatly improves patient access to treatment. Patients can now receive cell therapy without having to wait for a long and complex manufacturing period.
Phase 1 Data and Competitive Advantage
The 'KLN-1010' therapy, currently in development, is showing promising results in the Phase 1 'inMMyCAR' study (NCT07075185) for patients with relapsed/refractory multiple myeloma. Recent data show that all 18 patients who received the therapy achieved an overall objective response rate (ORR) of 100%, with minimal residual disease (MRD) negativity induced in just one month. This demonstrates a strong competitive advantage over existing approved ex vivo CAR-T therapies, such as Carvykti from Johnson & Johnson and Abecma from BMS, in terms of both efficacy and the fact that it is an off-the-shelf drug that can be administered immediately. In particular, it works without lymphodepleting chemotherapy, minimizing the burden of side effects on patients.
Restructuring of the Multiple Myeloma Market and Future Prospects
The global multiple myeloma market is estimated to be worth approximately $31 billion by 2026, and the incidence of new diagnoses continues to increase with the aging population. Through this acquisition, Eli Lilly has significantly strengthened its oncology genetic medicine portfolio and solidified its position as a next-generation oncology leader. As Phase 2 and 3 clinical trials are launched, it is expected to rapidly replace bispecific antibodies and conventional chemotherapy, changing the paradigm of standard of care. In the long term, the possibility of expanding into solid tumors is also open, which is expected to create synergies across Lilly's oncology pipeline.
From an investor's perspective, Eli Lilly's $7 billion deal, including a $3.25 billion upfront payment, secures a clear technological advantage over existing ex vivo CAR-T competitors such as Carvykti in the $31 billion multiple myeloma market. From a researcher's perspective, the 100% objective response rate (ORR) data and the in vivo gene delivery mechanism of 'KLN-1010', which is in Phase 1 clinical trials, will be a new milestone in the development of cell and gene therapies. For industry professionals, it is considered a signal for a paradigm shift in the manufacturing and logistics processes of cell therapies, which have traditionally been complex and costly, to an 'off-the-shelf' approach. In the medium to long term, this platform is expected to expand beyond multiple myeloma to various hematological malignancies and solid tumor pipelines, dramatically driving research and development investment and demand for specialized personnel in related fields.
Source: BioPharma Dive (rss)